Zika Virus Test Update: Saint Paul, MN March 10, 2016
MD Biosciences announces that it will proceed with the Zika test services following clarification with the FDA regarding any pre-market approval requirements pertaining to this assay. Testing services will not be offered pending this clarification.
Saint Paul, MN, USA - February 29, 2016, - MD Biosciences, Inc. (mdbiosciences.com) Clinical and Diagnostics Services Laboratory announces the release of its rapid assay to detect the virus in human blood and urine samples. The nucleic acid test can be performed in a few hours in blood, plasma, serum or urine samples. The test is specific for the Zika virus and was shown not to cross react with other infectious viruses such as Dengue, West Nile or Chikunguya. The laboratory developed test is available immediately
The World Health Organization stated that the spread of the mosquito-borne virus will grow explosively throughout the Americas. According to the CDC, the virus has also been shown to be transmitted through sexual contact. Upwards of four million infections are expected in the region. Close to 80% of infections are asymptomatic while others suffer from fever, rash, joint aches and other hallmarks. A steep increase in birth defects and Guillain-Barre syndrome has correlated to the spread of the virus. The explosive spread of the virus, along with major crowd and traveller-related events such as this year’s Olympic Games in Brazil, have underscored the need for steps in fighting the spread of the virus, including the ability to rapidly and specifically identify the infection.
Eddie Moradian, Chief Executive Officer at MD Biosciences, stated, “We are extremely proud of our CLIA diagnostics laboratory’s ability to provide a reliable, accurate and rapid method of testing for Zika virus. This demonstrates our commitment in placing our expertise, knowledge and infrastructure for the betterment of health, in the US and throughout the world, whether through the development of more advanced diagnostics or by advancing newer, better and more efficient therapies."
About MD Biosciences
MD Biosciences is a leading provider of clinical and preclinical services with over 25 years of experience in the clinical diagnostics and preclinical research areas. Services are provided for cancer, inflammatory, metabolic and neurological diseases. MD Biosciences laboratories provide extensive experience in working with biomarkers and developing validated laboratory assays. MD Biosciences operates through its facilities and laboratories in the United States, Switzerland and Israel.
Located in Saint Paul, MN, MD Biosciences' Clinical and Diagnostics Services Laboratory is a CLIA accredited laboratory for high complexity testing. All testing is performed under stringent guidelines in state of the art laboratories. Other services include clinically relevant tests for genetic markers of diseases including various cancers.
Inquiries may be directed to: Susan Belzer, Vice President, MD Biosciences Clinical Diagnostics Laboratory
by e-mail: clinlab@mdbiosciences.com
by telephone to 1-888-USMDBIO (1-888-876-3246) or (651-641-1770).
With a multifaceted approach to assessment of neurological diseases, specializations include pain-related work, neurodegenerative diseases including Parkinson's, neuro-inflammatory diseases such as Multiple Sclerosis (MS), and capabilities in stroke and cerebral ischemia. Preclinical models are complimented by in house histology, biomarker analysis and electrophysiology capabilities. Finally, our unique porcine models share a high degree of similarity to humans, thus offering greater clinical efficacy that serve to augment and accelerate your program towards their next objectives and milestones.
